What is HC Wainwright’s Estimate for AGIO FY2025 Earnings?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities research analysts at HC Wainwright raised their FY2025 EPS estimates for Agios Pharmaceuticals in a research note issued on Wednesday, November 19th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings of ($7.19) per share for the year, up from their previous forecast of ($7.21). HC Wainwright has a “Buy” rating and a $48.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.92) EPS, Q1 2026 earnings at ($2.04) EPS, Q2 2026 earnings at ($2.12) EPS, Q3 2026 earnings at ($2.10) EPS, Q4 2026 earnings at ($2.11) EPS, FY2026 earnings at ($8.37) EPS, FY2027 earnings at ($7.87) EPS, FY2028 earnings at ($6.61) EPS and FY2029 earnings at ($4.63) EPS.

Several other analysts have also recently issued reports on AGIO. Zacks Research upgraded Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 4th. Bank of America reduced their price objective on shares of Agios Pharmaceuticals from $54.00 to $32.00 and set a “buy” rating on the stock in a research report on Thursday. Leerink Partnrs upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday. Finally, Leerink Partners upgraded shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their price target for the stock from $40.00 to $34.00 in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $36.00.

Agios Pharmaceuticals Stock Up 2.7%

NASDAQ:AGIO opened at $25.24 on Monday. The business’s 50-day simple moving average is $39.91 and its two-hundred day simple moving average is $36.91. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $62.45. The stock has a market cap of $1.47 billion, a PE ratio of -3.61 and a beta of 0.89.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) EPS for the quarter, beating the consensus estimate of ($1.93) by $0.15. The firm had revenue of $12.90 million for the quarter, compared to the consensus estimate of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The company’s revenue was up 43.3% on a year-over-year basis. During the same period last year, the firm earned $16.22 EPS.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Horizon Corp purchased a new position in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $45,000. NewEdge Advisors LLC bought a new stake in Agios Pharmaceuticals in the first quarter worth $40,000. CWM LLC lifted its position in Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 996 shares during the last quarter. Quantbot Technologies LP purchased a new position in Agios Pharmaceuticals during the third quarter worth $79,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Agios Pharmaceuticals by 16.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 320 shares during the last quarter.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Theodore James Jr. Washburn sold 8,546 shares of the stock in a transaction on Friday, September 5th. The shares were sold at an average price of $36.87, for a total transaction of $315,091.02. Following the completion of the transaction, the insider owned 868 shares in the company, valued at $32,003.16. This trade represents a 90.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Cecilia Jones sold 3,651 shares of Agios Pharmaceuticals stock in a transaction on Friday, September 26th. The stock was sold at an average price of $36.77, for a total transaction of $134,247.27. Following the completion of the transaction, the chief financial officer directly owned 33,870 shares of the company’s stock, valued at $1,245,399.90. The trade was a 9.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,099 shares of company stock valued at $620,092 over the last 90 days. 4.93% of the stock is owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.